ATS 2019 Virtual Final Program

• understand the issues regarding adjunctive corticosteroid therapy of severe pneumonia with patients, since the committee will be more conservative in its recommendations than recent literature. Much has changed regarding treatment of community-acquired pneumonia since the last IDSA/ATS guidelines were published in 2007. The symposium speakers are experts in pneumonia, and will discuss the use of adjunctive steroids, empiric antibiotics, site of care determination, use of cultures and molecular diagnostics including procalcitonin, and identifying patients at risk for antibiotic resistant pathogens. Controversies in treating patients with community-acquired pneumonia will be addressed. Speakers will also discuss methods for local implementation of recommended processes of care, including computerized clinical decision support. Chairing: M.S. Niederman, MD, New York, NY E.M. Mortensen, MD, Farmington, CT 2:15 Introduction J. Metlay, MD, PhD, Boston, MA 2:30 Site of Care N.C. Dean, MD, Murray, UT 2:45 Identifying the Pathogen: Cultures, Molecular Methods, and Biomarkers K.A. Crothers, MD, Seattle, WA 3:05 Empiric Antibiotic Selection M.L. Metersky, MD, Farmington, CT 3:20 Selecting Patients for Empiric Broad Spectrum Antibiotics M.I. Restrepo, MD, MSc, PhD, San Antonio, TX 3:45 Antibiotic Deescalation and Duration of Therapy A. Anzueto, MD, ATSF, San Antonio, TX 4:00 Adjunctive Steroids for Patients with CAP G.W. Waterer, MBBS, MBA, PhD, Perth, Australia CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 A90 ICU-ACQUIRED WEAKNESS: A RAPID-FIRE DISCUSSION OF EMERGING ISSUES AND NEW INSIGHTS Assemblies on Critical Care; Respiratory Structure and Function 2:15 p.m. - 4:15 p.m. OMNI DALLAS DOWNTOWN Dallas Ballroom D/H (Level 3) Target Audience Adult and pediatric critical care clinicians and researchers Objectives At the conclusion of this session, the participant will be able to: • recognize potentially modifiable mechanisms of muscle weakness in critical illness; • appreciate the respective contributions of limb and diaphragm weakness and post-extubation swallowing dysfunction to clinical outcomes of critical illness both within and beyond the ICU; • describe evidence-based and emerging strategies for preventing and treating limb and diaphragm weakness in critically ill patients This session will provide a state of the art overview of emerging mechanistic and clinical insights related to ICU-acquired weakness affecting the limb muscles, respiratory muscles, and pharyngeal muscles. The session incorporates 9 rapid fire presentations highlighting a broad range of key issues. The focus of the session will progress from mechanisms of injury to outcomes and finally to emerging interventions, followed by a 25-minute panel Q&A discussion. Chairing: E.C. Goligher, MD, PhD, Toronto, Canada M. Kho, PT, PhD, Hamilton, Canada C.T. Hough, MD, MSc, Seattle, WA 2:15 Pathophysiology of Muscle Fatigue, Injury, and Weakness: A Primer W.D. Reid, PhD, Toronto, Canada 2:25 Diaphragm Muscle Weakness in the ICU: Inevitable or Avoidable? L.J. Brochard, MD, Toronto, Canada 2:35 Limb Muscle Weakness in the ICU: Inevitable or Avoidable? C.T. Hough, MD, MSc, Seattle, WA 2:45 Diaphragm Weakness vs. Limb Muscle Weakness: Same Disease? Same Outcome? M. Dres, MD, PhD, Paris, France 2:55 Beyond the ICU: Impact of ICU-Acquired Weakness on ICU Survivorship D.M. Needham, MD, PhD, Baltimore, MD 3:05 Emerging Insights on Post-Extubation Swallowing Dysfunction M. Brodsky, PhD, Baltimore, MD 3:15 Diaphragm-Protective Ventilation: The Next Frontier? E.C. Goligher, MD, PhD, Toronto, Canada 3:25 Emerging Strategies for Limb Muscle Rehabilitation in the ICU M. Kho, PT, PhD, Hamilton, Canada 3:35 Emerging Strategies for Diaphragm Muscle Rehabilitation in the ICU B. Bissett, PT, Canberra, Australia 3:45 Panel Q&A Discussion E.C. Goligher, MD, PhD, Toronto, Canada BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 A91 WHAT YOU CAN’T SEE MIGHT HURT YOU: THE INTERPLAY BETWEEN THE MICROBIOME AND IMMUNITY IN LUNG DISEASE Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pulmonary Infections and Tuberculosis; Respiratory Cell and Molecular Biology; Sleep and Respiratory Neurobiology 2:15 p.m. - 4:15 p.m. KBHCCD Room D220/D227 (Level 2) ATS 2019 • Dallas, TX SUNDAY • MAY 19 103 SUNDAY AFTERNOON